Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy (Q39655487)

13 September 2017

Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy (English)

1 reference

Adaptive radiation therapy

13 September 2017

0 references

1 reference

3

1 reference

13 September 2017

4

Deborah Kuban

1 reference

13 September 2017

Rex Cheung

1

1 reference

PubMed ID

12873666

13 September 2017

Susan L Tucker

series ordinal

2

1 reference

PubMed ID

12873666

13 September 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

International Journal of Radiation Oncology Biology Physics

13 September 2017

1 reference

13 September 2017

56

1 reference

13 September 2017

5

1 reference

13 September 2017

1234-1240

1 reference

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Dose selection for prostate cancer patients based on dose comparison and dose response studies

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

External beam radiotherapy dose response of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Quantifying the position and steepness of radiation dose-response curves

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

27-Year mortality in the Western collaborative group study: construction of risk groups by recursive partitioning

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Long-term effects of androgen deprivation therapy in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

Brachytherapy radiation doses to the neurovascular bundles

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900278-5

7 January 2021

10.1016/S0360-3016(03)00278-5

Identifiers

DOI

1 reference

13 September 2017

1 reference

PubMed ID

12873666